Risk for hospitalized heart failure among new users of saxagliptin, sitagliptin, and other antihyperglycemic drugs: A retrospective cohort study

Annals of Internal Medicine

Volumn 164, Issue 11, 2016, Pages 705-714

  Toh, Sengwee ^a   Hampp, Christian ^b   Reichman, Marsha E ^b   Graham, David J ^b   Balakrishnan, Suchitra ^b   Pucino, Frank ^b   Hamilton, Jack ^c   Lendle, Samuel ^c   Iyer, Aarthi ^a   Rucker, Malcolm ^a   Pimentel, Madelyn ^a   Nathwani, Neesha ^a   Griffin, Marie R ^d   Brown, Nancy J ^e   Fireman, Bruce H ^c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^c DIVISION OF RESEARCH   (United States)

^d VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^e VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; INSULIN; LONG ACTING INSULIN; PIOGLITAZONE; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ADAMANTANE; DIPEPTIDE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; SULFONYLUREA DERIVATIVE;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; COHORT ANALYSIS; FEMALE; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; HAZARD RATIO; HEALTH CARE SYSTEM; HEALTH INSURANCE; HEART FAILURE; HOSPITAL DISCHARGE; HOSPITALIZED HEART FAILURE; HUMAN; ICD-9-CM; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRESCRIPTION; PRIORITY JOURNAL; PROPENSITY SCORE; RETROSPECTIVE STUDY; ANALOGS AND DERIVATIVES; CHEMICALLY INDUCED; DIABETES MELLITUS, TYPE 2; HOSPITALIZATION; MIDDLE AGED; RISK FACTOR;

ADAMANTANE; DIABETES MELLITUS, TYPE 2; DIPEPTIDES; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; FEMALE; HEART FAILURE; HOSPITALIZATION; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; SITAGLIPTIN PHOSPHATE; SULFONYLUREA COMPOUNDS; THIAZOLIDINEDIONES;

EID: 84973495982     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/M15-2568     Document Type: Article

References (36)

1. Deacon CF. Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: A comparative review. Diabetes Obes Metab. 2011; 13:7-18. [PMID: 21114598] doi:10.1111/j.1463-1326.2010.01306.x.
2. Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, et al; SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369:1317-26. [PMID: 23992601] doi:10.1056/NEJMoa1307684.
3. Zannad F, Cannon CP, Cushman WC, Bakris GL, Menon V, Perez AT, et al; EXAMINE Investigators. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: A multicentre, randomised, double-blind trial. Lancet. 2015;385:2067-76. [PMID: 25765696] doi:10.1016/S0140-6736(14)62225-X.
4. Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, et al; TECOS Study Group. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373:232-42. [PMID: 26052984] doi:10.1056/NEJMoa1501352.
5. Voors AA, van der Horst IC. Diabetes: A driver for heart failure. Heart. 2011;97:774-80. [PMID: 21474618] doi:10.1136/hrt.2009.183624.
6. McMurray JJ, Gerstein HC, Holman RR, Pfeffer MA. Heart failure: A cardiovascular outcome in diabetes that can no longer be ignored. Lancet Diabetes Endocrinol. 2014;2:843-51. [PMID: 24731668] doi:10.1016/S2213-8587(14)70031-2.
7. Selby J, Reichman ME, Graham D, Butler M, Hampp C, Levenson M, et al. A protocol for active surveillance of acute myocardial infarction in association with use of anti-diabetic agents. 2010. Accessed at www.mini-sentinel.org/work-products/Assessments/Mini-Sentinel-AMI-and-Anti-Diabetic-Agents-Protocol.pdf on 24 March 2016.
8. Fireman B, Toh S, Butler MG, Go AS, Joffe HV, Graham DJ, et al. A protocol for active surveillance of acute myocardial infarction in association with the use of a new antidiabetic pharmaceutical agent. Pharmacoepidemiol Drug Saf. 2012;21 Suppl 1:282-90. [PMID: 22262618] doi:10.1002/pds.2337.
9. Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol. 2003;158:915-20. [PMID: 14585769].
10. Rodbard HW, Jellinger PS, Davidson JA, Einhorn D, Garber AJ, Grunberger G, et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: An algorithm for glycemic control. Endocr Pract. 2009;15:540-59. [PMID: 19858063].
11. Behrman RE, Benner JS, Brown JS, McClellan M, Woodcock J, Platt R. Developing the Sentinel System-a national resource for evidence development. N Engl J Med. 2011;364:498-9. [PMID: 21226658] doi:10.1056/NEJMp1014427.
12. Platt R, Carnahan RM, Brown JS, Chrischilles E, Curtis LH, Hennessy S, et al. The U.S. Food and Drug Administration's Mini-Sentinel program: status and direction. Pharmacoepidemiol Drug Saf. 2012;21 Suppl 1:1-8. [PMID: 22262586] doi:10.1002/pds.2343.
13. Curtis LH, Weiner MG, Boudreau DM, Cooper WO, Daniel GW, Nair VP, et al. Design considerations, architecture, and use of the Mini-Sentinel distributed data system. Pharmacoepidemiol Drug Saf. 2012;21 Suppl 1:23-31. [PMID: 22262590] doi:10.1002/pds.2336.
14. Rosati K, Evans B, McGraw D. HIPAA and Common Rule Compliance in the Mini-Sentinel Pilot. Accessed at http://mini-sentinel.org/work-products/About-Us/HIPAA-and-CommonRuleCompliance-in-the-Mini-SentinelPilot.pdf on 11 October 2015.
15. McGraw D, Rosati K, Evans B. A policy framework for public health uses of electronic health data. Pharmacoepidemiol Drug Saf. 2012;21 Suppl 1:18-22. [PMID: 22262589] doi:10.1002/pds.2319.
16. Hampp C, Borders-Hemphill V, Moeny DG, Wysowski DK. Use of antidiabetic drugs in the U.S., 2003-2012. Diabetes Care. 2014;37: 1367-74. [PMID: 24623020] doi:10.2337/dc13-2289.
17. Saczynski JS, Andrade SE, Harrold LR, Tjia J, Cutrona SL, Dodd KS, et al. A systematic review of validated methods for identifying heart failure using administrative data. Pharmacoepidemiol Drug Saf. 2012;21 Suppl 1:129-40. [PMID: 22262599] doi:10.1002/pds.2313.
18. Glynn RJ, Gagne JJ, Schneeweiss S. Role of disease risk scores in comparative effectiveness research with emerging therapies. Pharmacoepidemiol Drug Saf. 2012;21 Suppl 2:138-47. [PMID: 22552989] doi:10.1002/pds.3231.
19. Schneeweiss S. A basic study design for expedited safety signal evaluation based on electronic healthcare data. Pharmacoepidemiol Drug Saf. 2010;19:858-68. [PMID: 20681003] doi:10.1002/pds.1926.
20. Parsons LS. Reducing Bias in a Propensity Score Matched-Pair Sample Using Greedy Matching Techniques. Presented at the Twenty-Sixth Annual SAS Users Group International Conference (SUGI 26), Long Beach, California, 22-25 April 2001. Paper 214-26.
21. Psaty BM, Breckenridge AM. Mini-Sentinel and regulatory science- big data rendered fit and functional. N Engl J Med. 2014;370: 2165-7. [PMID: 24897081] doi:10.1056/NEJMp1401664.
22. U.S. Food and Drug Administration. Guidance for Industry: Diabetes Mellitus-Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes. Silver Spring, MD: U.S. Food and Drug Administration; 2008. Accessed at www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071627.pdf on 11 October 2015.
23. U.S. Food and Drug Administration. Guidance for Industry: Diabetes Mellitus-Developing Drugs and Therapeutic Biologics for Treatment and Prevention. Silver Spring, MD: U.S. Food and Drug Administration; 2008. Accessed at www.fda.gov/downloads/Drugs/.../Guidances/ucm071624.pdfon 11 October 2015.
24. European Medicines Agency. Guideline on Clinical Investigation of Medicinal Products in the Treatment of Diabetes Mellitus. London: European Medicines Agency; 2010. Accessed at www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2010/02/WC500073570.pdf on 11 October 2015.
25. Scirica BM, Braunwald E, Raz I, Cavender MA, Morrow DA, Jarolim P, et al; SAVOR-TIMI 53 Steering Committee and Investigators∗. Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. Circulation. 2014;130: 1579-88. [PMID: 25189213] doi:10.1161/CIRCULATIONAHA.114.010389.
26. Lago RM, Singh PP, Nesto RW. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: A meta-analysis of randomised clinical trials. Lancet. 2007;370:1129-36. [PMID: 17905165].
27. Nichols GA, Gullion CM, Koro CE, Ephross SA, Brown JB. The incidence of congestive heart failure in type 2 diabetes: An update. Diabetes Care. 2004;27:1879-84. [PMID: 15277411].
28. McAlister FA, Eurich DT, Majumdar SR, Johnson JA. The risk of heart failure in patients with type 2 diabetes treated with oral agent monotherapy. Eur J Heart Fail. 2008;10:703-8. [PMID: 18571471] doi:10.1016/j.ejheart.2008.05.013.
29. Kannel WB, Hjortland M, Castelli WP. Role of diabetes in congestive heart failure: The Framingham study. Am J Cardiol. 1974;34: 29-34. [PMID: 4835750].
30. Monami M, Dicembrini I, Mannucci E. Dipeptidyl peptidase-4 inhibitors and heart failure: A meta-analysis of randomized clinical trials. Nutr Metab Cardiovasc Dis. 2014;24:689-97. [PMID: 24793580] doi:10.1016/j.numecd.2014.01.017.
31. Wu S, Hopper I, Skiba M, Krum H. Dipeptidyl peptidase-4 inhibitors and cardiovascular outcomes: meta-analysis of randomized clinical trials with 55, 141 participants. Cardiovasc Ther. 2014;32:147-58. [PMID: 24750644] doi:10.1111/1755-5922.12075.
32. Weir DL, McAlister FA, Senthilselvan A, Minhas-Sandhu JK, Eurich DT. Sitagliptin use in patients with diabetes and heart failure: A population-based retrospective cohort study. JACC Heart Fail. 2014; 2:573-82. [PMID: 24998080] doi:10.1016/j.jchf.2014.04.005.
33. Chen DY, Wang SH, Mao CT, Tsai ML, Lin YS, Chou CC, et al. Sitagliptin and cardiovascular outcomes in diabetic patients with chronic kidney disease and acute myocardial infarction: A nationwide cohort study. Int J Cardiol. 2015;181:200-6. [PMID: 25528312] doi:10.1016/j.ijcard.2014.12.029.
34. Kim SC, Glynn RJ, Liu J, Everett BM, Goldfine AB. Dipeptidyl peptidase-4 inhibitors do not increase the risk of cardiovascular events in type 2 diabetes: A cohort study. Acta Diabetol. 2014;51:1015-23. [PMID: 25311055] doi:10.1007/s00592-014-0663-2.
35. Fu AZ, Johnston SS, Ghannam A, Tsai K, Cappell K, Fowler R, et al. Association between hospitalization for heart failure and dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes: An observational study. Diabetes Care. 2016. [PMID: 26740636].
36. Yu OH, Filion KB, Azoulay L, Patenaude V, Majdan A, Suissa S. Incretin-based drugs and the risk of congestive heart failure. Diabetes Care. 2015;38:277-84. [PMID: 25205143] doi:10.2337/dc14-1459.